nodes	percent_of_prediction	percent_of_DWPC	metapath
Vemurafenib—ALB—multiple sclerosis	0.256	1	CbGaD
Vemurafenib—ABCC1—Mitoxantrone—multiple sclerosis	0.0839	0.165	CbGbCtD
Vemurafenib—ABCG2—Cladribine—multiple sclerosis	0.0769	0.151	CbGbCtD
Vemurafenib—ABCG2—Mitoxantrone—multiple sclerosis	0.0561	0.11	CbGbCtD
Vemurafenib—CYP2D6—Fingolimod—multiple sclerosis	0.0406	0.0798	CbGbCtD
Vemurafenib—ABCC1—Methotrexate—multiple sclerosis	0.0349	0.0688	CbGbCtD
Vemurafenib—ALB—Prednisone—multiple sclerosis	0.0321	0.0632	CbGbCtD
Vemurafenib—ABCG2—Dexamethasone—multiple sclerosis	0.0291	0.0573	CbGbCtD
Vemurafenib—CYP3A4—Fingolimod—multiple sclerosis	0.0258	0.0508	CbGbCtD
Vemurafenib—ABCG2—Methotrexate—multiple sclerosis	0.0234	0.046	CbGbCtD
Vemurafenib—CYP3A4—Methylprednisolone—multiple sclerosis	0.0166	0.0327	CbGbCtD
Vemurafenib—ALB—Methotrexate—multiple sclerosis	0.0161	0.0317	CbGbCtD
Vemurafenib—CYP3A4—Triamcinolone—multiple sclerosis	0.0126	0.0248	CbGbCtD
Vemurafenib—CYP3A4—Mitoxantrone—multiple sclerosis	0.0121	0.0239	CbGbCtD
Vemurafenib—CYP3A4—Betamethasone—multiple sclerosis	0.0108	0.0213	CbGbCtD
Vemurafenib—CYP3A4—Prednisolone—multiple sclerosis	0.0107	0.021	CbGbCtD
Vemurafenib—CYP3A4—Prednisone—multiple sclerosis	0.0101	0.0198	CbGbCtD
Vemurafenib—CYP2D6—Dexamethasone—multiple sclerosis	0.00988	0.0195	CbGbCtD
Vemurafenib—CYP3A4—Dexamethasone—multiple sclerosis	0.00629	0.0124	CbGbCtD
Vemurafenib—Alopecia—Azathioprine—multiple sclerosis	0.000395	0.00335	CcSEcCtD
Vemurafenib—Dry skin—Prednisolone—multiple sclerosis	0.000393	0.00333	CcSEcCtD
Vemurafenib—Infection—Cladribine—multiple sclerosis	0.000388	0.00329	CcSEcCtD
Vemurafenib—Nervous system disorder—Cladribine—multiple sclerosis	0.000383	0.00325	CcSEcCtD
Vemurafenib—Skin disorder—Cladribine—multiple sclerosis	0.00038	0.00322	CcSEcCtD
Vemurafenib—Vasculitis—Methotrexate—multiple sclerosis	0.000368	0.00311	CcSEcCtD
Vemurafenib—Hypotension—Cladribine—multiple sclerosis	0.000365	0.00309	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.000356	0.00302	CcSEcCtD
Vemurafenib—Decreased appetite—Cladribine—multiple sclerosis	0.00034	0.00288	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.000337	0.00286	CcSEcCtD
Vemurafenib—Fatigue—Cladribine—multiple sclerosis	0.000337	0.00286	CcSEcCtD
Vemurafenib—Constipation—Cladribine—multiple sclerosis	0.000334	0.00283	CcSEcCtD
Vemurafenib—Myalgia—Azathioprine—multiple sclerosis	0.000331	0.00281	CcSEcCtD
Vemurafenib—Arthralgia—Azathioprine—multiple sclerosis	0.000331	0.00281	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.000329	0.00279	CcSEcCtD
Vemurafenib—Dry skin—Dexamethasone—multiple sclerosis	0.000328	0.00278	CcSEcCtD
Vemurafenib—Dry skin—Betamethasone—multiple sclerosis	0.000328	0.00278	CcSEcCtD
Vemurafenib—Chills—Mitoxantrone—multiple sclerosis	0.000324	0.00275	CcSEcCtD
Vemurafenib—Neoplasm—Methotrexate—multiple sclerosis	0.000324	0.00275	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisolone—multiple sclerosis	0.000324	0.00274	CcSEcCtD
Vemurafenib—Alopecia—Mitoxantrone—multiple sclerosis	0.00032	0.00271	CcSEcCtD
Vemurafenib—Infection—Azathioprine—multiple sclerosis	0.000316	0.00268	CcSEcCtD
Vemurafenib—Erythema—Mitoxantrone—multiple sclerosis	0.000315	0.00267	CcSEcCtD
Vemurafenib—Body temperature increased—Cladribine—multiple sclerosis	0.000309	0.00262	CcSEcCtD
Vemurafenib—Skin disorder—Azathioprine—multiple sclerosis	0.000309	0.00262	CcSEcCtD
Vemurafenib—Dysgeusia—Mitoxantrone—multiple sclerosis	0.000308	0.00261	CcSEcCtD
Vemurafenib—Back pain—Mitoxantrone—multiple sclerosis	0.000304	0.00258	CcSEcCtD
Vemurafenib—Infestation NOS—Methylprednisolone—multiple sclerosis	0.000303	0.00257	CcSEcCtD
Vemurafenib—Infestation—Methylprednisolone—multiple sclerosis	0.000303	0.00257	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Triamcinolone—multiple sclerosis	0.000298	0.00252	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Methylprednisolone—multiple sclerosis	0.000297	0.00252	CcSEcCtD
Vemurafenib—Hypotension—Azathioprine—multiple sclerosis	0.000297	0.00252	CcSEcCtD
Vemurafenib—Photosensitivity—Methotrexate—multiple sclerosis	0.000297	0.00251	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.00029	0.00245	CcSEcCtD
Vemurafenib—Hypersensitivity—Cladribine—multiple sclerosis	0.000288	0.00244	CcSEcCtD
Vemurafenib—Dry skin—Prednisone—multiple sclerosis	0.000286	0.00242	CcSEcCtD
Vemurafenib—RAF1—brainstem—multiple sclerosis	0.000285	0.0884	CbGeAlD
Vemurafenib—Asthenia—Cladribine—multiple sclerosis	0.00028	0.00238	CcSEcCtD
Vemurafenib—Weight decreased—Betamethasone—multiple sclerosis	0.00028	0.00237	CcSEcCtD
Vemurafenib—Weight decreased—Dexamethasone—multiple sclerosis	0.00028	0.00237	CcSEcCtD
Vemurafenib—Pruritus—Cladribine—multiple sclerosis	0.000276	0.00234	CcSEcCtD
Vemurafenib—Cough—Mitoxantrone—multiple sclerosis	0.000275	0.00233	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.000274	0.00232	CcSEcCtD
Vemurafenib—BRAF—midbrain—multiple sclerosis	0.000272	0.0846	CbGeAlD
Vemurafenib—Neuropathy peripheral—Betamethasone—multiple sclerosis	0.00027	0.00229	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Dexamethasone—multiple sclerosis	0.00027	0.00229	CcSEcCtD
Vemurafenib—Arthralgia—Mitoxantrone—multiple sclerosis	0.000268	0.00227	CcSEcCtD
Vemurafenib—Myalgia—Mitoxantrone—multiple sclerosis	0.000268	0.00227	CcSEcCtD
Vemurafenib—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.000267	0.00227	CcSEcCtD
Vemurafenib—Diarrhoea—Cladribine—multiple sclerosis	0.000267	0.00227	CcSEcCtD
Vemurafenib—Dizziness—Cladribine—multiple sclerosis	0.000258	0.00219	CcSEcCtD
Vemurafenib—Erythema—Prednisolone—multiple sclerosis	0.000258	0.00219	CcSEcCtD
Vemurafenib—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000257	0.00218	CcSEcCtD
Vemurafenib—Infection—Mitoxantrone—multiple sclerosis	0.000255	0.00216	CcSEcCtD
Vemurafenib—Eye disorder—Methylprednisolone—multiple sclerosis	0.000254	0.00216	CcSEcCtD
Vemurafenib—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000253	0.00214	CcSEcCtD
Vemurafenib—Body temperature increased—Azathioprine—multiple sclerosis	0.000251	0.00213	CcSEcCtD
Vemurafenib—Skin disorder—Mitoxantrone—multiple sclerosis	0.00025	0.00211	CcSEcCtD
Vemurafenib—Vomiting—Cladribine—multiple sclerosis	0.000248	0.00211	CcSEcCtD
Vemurafenib—Angiopathy—Methylprednisolone—multiple sclerosis	0.000247	0.00209	CcSEcCtD
Vemurafenib—Rash—Cladribine—multiple sclerosis	0.000246	0.00209	CcSEcCtD
Vemurafenib—Dermatitis—Cladribine—multiple sclerosis	0.000246	0.00209	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methylprednisolone—multiple sclerosis	0.000245	0.00208	CcSEcCtD
Vemurafenib—Headache—Cladribine—multiple sclerosis	0.000245	0.00207	CcSEcCtD
Vemurafenib—Weight decreased—Prednisone—multiple sclerosis	0.000244	0.00206	CcSEcCtD
Vemurafenib—Hypotension—Mitoxantrone—multiple sclerosis	0.00024	0.00203	CcSEcCtD
Vemurafenib—Erythema—Triamcinolone—multiple sclerosis	0.000237	0.00201	CcSEcCtD
Vemurafenib—Malnutrition—Methylprednisolone—multiple sclerosis	0.000237	0.00201	CcSEcCtD
Vemurafenib—Erythema—Methylprednisolone—multiple sclerosis	0.000237	0.00201	CcSEcCtD
Vemurafenib—Neuropathy peripheral—Prednisone—multiple sclerosis	0.000235	0.00199	CcSEcCtD
Vemurafenib—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000234	0.00199	CcSEcCtD
Vemurafenib—Hypersensitivity—Azathioprine—multiple sclerosis	0.000234	0.00198	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000234	0.00198	CcSEcCtD
Vemurafenib—Dysgeusia—Triamcinolone—multiple sclerosis	0.000233	0.00197	CcSEcCtD
Vemurafenib—Nausea—Cladribine—multiple sclerosis	0.000232	0.00197	CcSEcCtD
Vemurafenib—Eye disorder—Betamethasone—multiple sclerosis	0.000231	0.00196	CcSEcCtD
Vemurafenib—Eye disorder—Dexamethasone—multiple sclerosis	0.000231	0.00196	CcSEcCtD
Vemurafenib—Back pain—Triamcinolone—multiple sclerosis	0.00023	0.00195	CcSEcCtD
Vemurafenib—Angiopathy—Betamethasone—multiple sclerosis	0.000225	0.0019	CcSEcCtD
Vemurafenib—Angiopathy—Dexamethasone—multiple sclerosis	0.000225	0.0019	CcSEcCtD
Vemurafenib—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000223	0.00189	CcSEcCtD
Vemurafenib—Eosinophilia—Methotrexate—multiple sclerosis	0.000223	0.00189	CcSEcCtD
Vemurafenib—Fatigue—Mitoxantrone—multiple sclerosis	0.000221	0.00188	CcSEcCtD
Vemurafenib—Constipation—Mitoxantrone—multiple sclerosis	0.00022	0.00186	CcSEcCtD
Vemurafenib—Alopecia—Dexamethasone—multiple sclerosis	0.000219	0.00185	CcSEcCtD
Vemurafenib—Alopecia—Betamethasone—multiple sclerosis	0.000219	0.00185	CcSEcCtD
Vemurafenib—Diarrhoea—Azathioprine—multiple sclerosis	0.000217	0.00184	CcSEcCtD
Vemurafenib—Erythema—Dexamethasone—multiple sclerosis	0.000215	0.00183	CcSEcCtD
Vemurafenib—Erythema—Betamethasone—multiple sclerosis	0.000215	0.00183	CcSEcCtD
Vemurafenib—Connective tissue disorder—Prednisone—multiple sclerosis	0.000212	0.0018	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000211	0.00179	CcSEcCtD
Vemurafenib—BRAF—cerebellum—multiple sclerosis	0.000211	0.0654	CbGeAlD
Vemurafenib—Dizziness—Azathioprine—multiple sclerosis	0.00021	0.00178	CcSEcCtD
Vemurafenib—Cough—Triamcinolone—multiple sclerosis	0.000207	0.00176	CcSEcCtD
Vemurafenib—Photosensitivity reaction—Methotrexate—multiple sclerosis	0.000205	0.00174	CcSEcCtD
Vemurafenib—Body temperature increased—Mitoxantrone—multiple sclerosis	0.000203	0.00172	CcSEcCtD
Vemurafenib—Myalgia—Triamcinolone—multiple sclerosis	0.000202	0.00171	CcSEcCtD
Vemurafenib—Vomiting—Azathioprine—multiple sclerosis	0.000202	0.00171	CcSEcCtD
Vemurafenib—Myalgia—Methylprednisolone—multiple sclerosis	0.000202	0.00171	CcSEcCtD
Vemurafenib—Arthralgia—Methylprednisolone—multiple sclerosis	0.000202	0.00171	CcSEcCtD
Vemurafenib—Eye disorder—Prednisone—multiple sclerosis	0.000201	0.00171	CcSEcCtD
Vemurafenib—Infestation—Methotrexate—multiple sclerosis	0.000201	0.0017	CcSEcCtD
Vemurafenib—Infestation NOS—Methotrexate—multiple sclerosis	0.000201	0.0017	CcSEcCtD
Vemurafenib—Rash—Azathioprine—multiple sclerosis	0.0002	0.0017	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.0002	0.0017	CcSEcCtD
Vemurafenib—Dermatitis—Azathioprine—multiple sclerosis	0.0002	0.0017	CcSEcCtD
Vemurafenib—Headache—Azathioprine—multiple sclerosis	0.000199	0.00169	CcSEcCtD
Vemurafenib—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000199	0.00169	CcSEcCtD
Vemurafenib—RAF1—medulla oblongata—multiple sclerosis	0.000198	0.0617	CbGeAlD
Vemurafenib—Angiopathy—Prednisone—multiple sclerosis	0.000196	0.00166	CcSEcCtD
Vemurafenib—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000194	0.00164	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000193	0.00164	CcSEcCtD
Vemurafenib—Infection—Triamcinolone—multiple sclerosis	0.000193	0.00163	CcSEcCtD
Vemurafenib—Infection—Methylprednisolone—multiple sclerosis	0.000192	0.00163	CcSEcCtD
Vemurafenib—Alopecia—Prednisone—multiple sclerosis	0.00019	0.00161	CcSEcCtD
Vemurafenib—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.00019	0.00161	CcSEcCtD
Vemurafenib—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000189	0.0016	CcSEcCtD
Vemurafenib—Nausea—Azathioprine—multiple sclerosis	0.000189	0.0016	CcSEcCtD
Vemurafenib—Skin disorder—Methylprednisolone—multiple sclerosis	0.000188	0.00159	CcSEcCtD
Vemurafenib—Malnutrition—Prednisone—multiple sclerosis	0.000188	0.00159	CcSEcCtD
Vemurafenib—Erythema—Prednisone—multiple sclerosis	0.000188	0.00159	CcSEcCtD
Vemurafenib—Asthenia—Mitoxantrone—multiple sclerosis	0.000184	0.00156	CcSEcCtD
Vemurafenib—Myalgia—Betamethasone—multiple sclerosis	0.000183	0.00155	CcSEcCtD
Vemurafenib—Myalgia—Dexamethasone—multiple sclerosis	0.000183	0.00155	CcSEcCtD
Vemurafenib—RAF1—midbrain—multiple sclerosis	0.000181	0.0564	CbGeAlD
Vemurafenib—Hypotension—Methylprednisolone—multiple sclerosis	0.000181	0.00153	CcSEcCtD
Vemurafenib—RAF1—spinal cord—multiple sclerosis	0.000177	0.055	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000177	0.0015	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.000176	0.00149	CcSEcCtD
Vemurafenib—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000176	0.00149	CcSEcCtD
Vemurafenib—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000176	0.00149	CcSEcCtD
Vemurafenib—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000176	0.00149	CcSEcCtD
Vemurafenib—Infection—Dexamethasone—multiple sclerosis	0.000175	0.00148	CcSEcCtD
Vemurafenib—Infection—Betamethasone—multiple sclerosis	0.000175	0.00148	CcSEcCtD
Vemurafenib—Nervous system disorder—Betamethasone—multiple sclerosis	0.000172	0.00146	CcSEcCtD
Vemurafenib—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000172	0.00146	CcSEcCtD
Vemurafenib—BRAF—brain—multiple sclerosis	0.000171	0.0531	CbGeAlD
Vemurafenib—Erythema multiforme—Methotrexate—multiple sclerosis	0.00017	0.00144	CcSEcCtD
Vemurafenib—Eye disorder—Methotrexate—multiple sclerosis	0.000168	0.00143	CcSEcCtD
Vemurafenib—Cardiac disorder—Methotrexate—multiple sclerosis	0.000167	0.00142	CcSEcCtD
Vemurafenib—Fatigue—Triamcinolone—multiple sclerosis	0.000167	0.00142	CcSEcCtD
Vemurafenib—Fatigue—Methylprednisolone—multiple sclerosis	0.000167	0.00141	CcSEcCtD
Vemurafenib—Hypotension—Dexamethasone—multiple sclerosis	0.000164	0.00139	CcSEcCtD
Vemurafenib—Hypotension—Betamethasone—multiple sclerosis	0.000164	0.00139	CcSEcCtD
Vemurafenib—Angiopathy—Methotrexate—multiple sclerosis	0.000163	0.00139	CcSEcCtD
Vemurafenib—Vomiting—Mitoxantrone—multiple sclerosis	0.000163	0.00138	CcSEcCtD
Vemurafenib—Mediastinal disorder—Methotrexate—multiple sclerosis	0.000162	0.00138	CcSEcCtD
Vemurafenib—Rash—Mitoxantrone—multiple sclerosis	0.000162	0.00137	CcSEcCtD
Vemurafenib—Dermatitis—Mitoxantrone—multiple sclerosis	0.000162	0.00137	CcSEcCtD
Vemurafenib—Chills—Methotrexate—multiple sclerosis	0.000162	0.00137	CcSEcCtD
Vemurafenib—Headache—Mitoxantrone—multiple sclerosis	0.000161	0.00136	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.00016	0.00136	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.00016	0.00136	CcSEcCtD
Vemurafenib—Myalgia—Prednisone—multiple sclerosis	0.00016	0.00135	CcSEcCtD
Vemurafenib—Arthralgia—Prednisone—multiple sclerosis	0.00016	0.00135	CcSEcCtD
Vemurafenib—Alopecia—Methotrexate—multiple sclerosis	0.000159	0.00135	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000159	0.00134	CcSEcCtD
Vemurafenib—Erythema—Methotrexate—multiple sclerosis	0.000157	0.00133	CcSEcCtD
Vemurafenib—Malnutrition—Methotrexate—multiple sclerosis	0.000157	0.00133	CcSEcCtD
Vemurafenib—Hypersensitivity—Prednisolone—multiple sclerosis	0.000155	0.00132	CcSEcCtD
Vemurafenib—Dysgeusia—Methotrexate—multiple sclerosis	0.000154	0.0013	CcSEcCtD
Vemurafenib—Body temperature increased—Triamcinolone—multiple sclerosis	0.000153	0.0013	CcSEcCtD
Vemurafenib—Anaphylactic shock—Prednisone—multiple sclerosis	0.000153	0.0013	CcSEcCtD
Vemurafenib—Decreased appetite—Dexamethasone—multiple sclerosis	0.000153	0.0013	CcSEcCtD
Vemurafenib—Decreased appetite—Betamethasone—multiple sclerosis	0.000153	0.0013	CcSEcCtD
Vemurafenib—Nausea—Mitoxantrone—multiple sclerosis	0.000153	0.00129	CcSEcCtD
Vemurafenib—Infection—Prednisone—multiple sclerosis	0.000152	0.00129	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000152	0.00129	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000152	0.00129	CcSEcCtD
Vemurafenib—Back pain—Methotrexate—multiple sclerosis	0.000152	0.00129	CcSEcCtD
Vemurafenib—Fatigue—Dexamethasone—multiple sclerosis	0.000152	0.00128	CcSEcCtD
Vemurafenib—Fatigue—Betamethasone—multiple sclerosis	0.000152	0.00128	CcSEcCtD
Vemurafenib—Nervous system disorder—Prednisone—multiple sclerosis	0.00015	0.00127	CcSEcCtD
Vemurafenib—RAF1—nervous system—multiple sclerosis	0.000149	0.0463	CbGeAlD
Vemurafenib—Skin disorder—Prednisone—multiple sclerosis	0.000149	0.00126	CcSEcCtD
Vemurafenib—RAF1—central nervous system—multiple sclerosis	0.000144	0.0446	CbGeAlD
Vemurafenib—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000143	0.00121	CcSEcCtD
Vemurafenib—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.000142	0.00121	CcSEcCtD
Vemurafenib—RAF1—cerebellum—multiple sclerosis	0.00014	0.0436	CbGeAlD
Vemurafenib—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.00014	0.00118	CcSEcCtD
Vemurafenib—Dizziness—Prednisolone—multiple sclerosis	0.000139	0.00118	CcSEcCtD
Vemurafenib—Asthenia—Triamcinolone—multiple sclerosis	0.000139	0.00118	CcSEcCtD
Vemurafenib—Body temperature increased—Betamethasone—multiple sclerosis	0.000139	0.00118	CcSEcCtD
Vemurafenib—Body temperature increased—Dexamethasone—multiple sclerosis	0.000139	0.00118	CcSEcCtD
Vemurafenib—Asthenia—Methylprednisolone—multiple sclerosis	0.000139	0.00118	CcSEcCtD
Vemurafenib—Pruritus—Triamcinolone—multiple sclerosis	0.000137	0.00116	CcSEcCtD
Vemurafenib—Cough—Methotrexate—multiple sclerosis	0.000137	0.00116	CcSEcCtD
Vemurafenib—Pruritus—Methylprednisolone—multiple sclerosis	0.000137	0.00116	CcSEcCtD
Vemurafenib—Myalgia—Methotrexate—multiple sclerosis	0.000134	0.00113	CcSEcCtD
Vemurafenib—Arthralgia—Methotrexate—multiple sclerosis	0.000134	0.00113	CcSEcCtD
Vemurafenib—Decreased appetite—Prednisone—multiple sclerosis	0.000133	0.00113	CcSEcCtD
Vemurafenib—Rash—Prednisolone—multiple sclerosis	0.000133	0.00113	CcSEcCtD
Vemurafenib—Dermatitis—Prednisolone—multiple sclerosis	0.000133	0.00113	CcSEcCtD
Vemurafenib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000133	0.00112	CcSEcCtD
Vemurafenib—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000132	0.00112	CcSEcCtD
Vemurafenib—Fatigue—Prednisone—multiple sclerosis	0.000132	0.00112	CcSEcCtD
Vemurafenib—Headache—Prednisolone—multiple sclerosis	0.000132	0.00112	CcSEcCtD
Vemurafenib—Constipation—Prednisone—multiple sclerosis	0.000131	0.00111	CcSEcCtD
Vemurafenib—Dizziness—Triamcinolone—multiple sclerosis	0.000128	0.00109	CcSEcCtD
Vemurafenib—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000128	0.00108	CcSEcCtD
Vemurafenib—Dizziness—Methylprednisolone—multiple sclerosis	0.000128	0.00108	CcSEcCtD
Vemurafenib—Infection—Methotrexate—multiple sclerosis	0.000127	0.00108	CcSEcCtD
Vemurafenib—Asthenia—Dexamethasone—multiple sclerosis	0.000126	0.00107	CcSEcCtD
Vemurafenib—Asthenia—Betamethasone—multiple sclerosis	0.000126	0.00107	CcSEcCtD
Vemurafenib—Nervous system disorder—Methotrexate—multiple sclerosis	0.000126	0.00106	CcSEcCtD
Vemurafenib—Nausea—Prednisolone—multiple sclerosis	0.000125	0.00106	CcSEcCtD
Vemurafenib—Pruritus—Betamethasone—multiple sclerosis	0.000124	0.00105	CcSEcCtD
Vemurafenib—Pruritus—Dexamethasone—multiple sclerosis	0.000124	0.00105	CcSEcCtD
Vemurafenib—Skin disorder—Methotrexate—multiple sclerosis	0.000124	0.00105	CcSEcCtD
Vemurafenib—Vomiting—Triamcinolone—multiple sclerosis	0.000123	0.00104	CcSEcCtD
Vemurafenib—Vomiting—Methylprednisolone—multiple sclerosis	0.000123	0.00104	CcSEcCtD
Vemurafenib—Rash—Triamcinolone—multiple sclerosis	0.000122	0.00104	CcSEcCtD
Vemurafenib—ORM1—spinal cord—multiple sclerosis	0.000122	0.038	CbGeAlD
Vemurafenib—Dermatitis—Triamcinolone—multiple sclerosis	0.000122	0.00103	CcSEcCtD
Vemurafenib—Rash—Methylprednisolone—multiple sclerosis	0.000122	0.00103	CcSEcCtD
Vemurafenib—Dermatitis—Methylprednisolone—multiple sclerosis	0.000122	0.00103	CcSEcCtD
Vemurafenib—Headache—Triamcinolone—multiple sclerosis	0.000121	0.00103	CcSEcCtD
Vemurafenib—Headache—Methylprednisolone—multiple sclerosis	0.000121	0.00103	CcSEcCtD
Vemurafenib—Body temperature increased—Prednisone—multiple sclerosis	0.000121	0.00103	CcSEcCtD
Vemurafenib—Diarrhoea—Dexamethasone—multiple sclerosis	0.00012	0.00102	CcSEcCtD
Vemurafenib—Diarrhoea—Betamethasone—multiple sclerosis	0.00012	0.00102	CcSEcCtD
Vemurafenib—Hypotension—Methotrexate—multiple sclerosis	0.00012	0.00101	CcSEcCtD
Vemurafenib—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000117	0.000988	CcSEcCtD
Vemurafenib—Dizziness—Dexamethasone—multiple sclerosis	0.000116	0.000985	CcSEcCtD
Vemurafenib—Dizziness—Betamethasone—multiple sclerosis	0.000116	0.000985	CcSEcCtD
Vemurafenib—Nausea—Triamcinolone—multiple sclerosis	0.000115	0.000976	CcSEcCtD
Vemurafenib—Nausea—Methylprednisolone—multiple sclerosis	0.000115	0.000973	CcSEcCtD
Vemurafenib—RAF1—brain—multiple sclerosis	0.000114	0.0354	CbGeAlD
Vemurafenib—Hypersensitivity—Prednisone—multiple sclerosis	0.000113	0.000956	CcSEcCtD
Vemurafenib—Vomiting—Betamethasone—multiple sclerosis	0.000112	0.000948	CcSEcCtD
Vemurafenib—Vomiting—Dexamethasone—multiple sclerosis	0.000112	0.000948	CcSEcCtD
Vemurafenib—Decreased appetite—Methotrexate—multiple sclerosis	0.000111	0.000943	CcSEcCtD
Vemurafenib—Rash—Dexamethasone—multiple sclerosis	0.000111	0.00094	CcSEcCtD
Vemurafenib—Rash—Betamethasone—multiple sclerosis	0.000111	0.00094	CcSEcCtD
Vemurafenib—Dermatitis—Dexamethasone—multiple sclerosis	0.000111	0.000939	CcSEcCtD
Vemurafenib—Dermatitis—Betamethasone—multiple sclerosis	0.000111	0.000939	CcSEcCtD
Vemurafenib—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.00011	0.000936	CcSEcCtD
Vemurafenib—Fatigue—Methotrexate—multiple sclerosis	0.00011	0.000935	CcSEcCtD
Vemurafenib—Headache—Dexamethasone—multiple sclerosis	0.00011	0.000934	CcSEcCtD
Vemurafenib—Headache—Betamethasone—multiple sclerosis	0.00011	0.000934	CcSEcCtD
Vemurafenib—Asthenia—Prednisone—multiple sclerosis	0.00011	0.000931	CcSEcCtD
Vemurafenib—Pruritus—Prednisone—multiple sclerosis	0.000108	0.000918	CcSEcCtD
Vemurafenib—Diarrhoea—Prednisone—multiple sclerosis	0.000105	0.000888	CcSEcCtD
Vemurafenib—Nausea—Betamethasone—multiple sclerosis	0.000104	0.000885	CcSEcCtD
Vemurafenib—Nausea—Dexamethasone—multiple sclerosis	0.000104	0.000885	CcSEcCtD
Vemurafenib—ORM1—nervous system—multiple sclerosis	0.000103	0.032	CbGeAlD
Vemurafenib—Dizziness—Prednisone—multiple sclerosis	0.000101	0.000858	CcSEcCtD
Vemurafenib—Body temperature increased—Methotrexate—multiple sclerosis	0.000101	0.000857	CcSEcCtD
Vemurafenib—ORM1—central nervous system—multiple sclerosis	9.91e-05	0.0308	CbGeAlD
Vemurafenib—Vomiting—Prednisone—multiple sclerosis	9.74e-05	0.000825	CcSEcCtD
Vemurafenib—Rash—Prednisone—multiple sclerosis	9.66e-05	0.000818	CcSEcCtD
Vemurafenib—Dermatitis—Prednisone—multiple sclerosis	9.65e-05	0.000818	CcSEcCtD
Vemurafenib—Headache—Prednisone—multiple sclerosis	9.59e-05	0.000813	CcSEcCtD
Vemurafenib—Hypersensitivity—Methotrexate—multiple sclerosis	9.43e-05	0.000799	CcSEcCtD
Vemurafenib—Asthenia—Methotrexate—multiple sclerosis	9.18e-05	0.000778	CcSEcCtD
Vemurafenib—Nausea—Prednisone—multiple sclerosis	9.1e-05	0.000771	CcSEcCtD
Vemurafenib—Pruritus—Methotrexate—multiple sclerosis	9.05e-05	0.000767	CcSEcCtD
Vemurafenib—Diarrhoea—Methotrexate—multiple sclerosis	8.76e-05	0.000742	CcSEcCtD
Vemurafenib—Dizziness—Methotrexate—multiple sclerosis	8.46e-05	0.000717	CcSEcCtD
Vemurafenib—ABCG2—medulla oblongata—multiple sclerosis	8.21e-05	0.0255	CbGeAlD
Vemurafenib—Vomiting—Methotrexate—multiple sclerosis	8.14e-05	0.00069	CcSEcCtD
Vemurafenib—Rash—Methotrexate—multiple sclerosis	8.07e-05	0.000684	CcSEcCtD
Vemurafenib—CYP2D6—brainstem—multiple sclerosis	8.07e-05	0.0251	CbGeAlD
Vemurafenib—Dermatitis—Methotrexate—multiple sclerosis	8.06e-05	0.000683	CcSEcCtD
Vemurafenib—Headache—Methotrexate—multiple sclerosis	8.02e-05	0.000679	CcSEcCtD
Vemurafenib—Nausea—Methotrexate—multiple sclerosis	7.6e-05	0.000644	CcSEcCtD
Vemurafenib—ABCG2—midbrain—multiple sclerosis	7.5e-05	0.0233	CbGeAlD
Vemurafenib—ABCG2—spinal cord—multiple sclerosis	7.32e-05	0.0227	CbGeAlD
Vemurafenib—ABCC1—cerebellum—multiple sclerosis	7.01e-05	0.0218	CbGeAlD
Vemurafenib—ALB—brain—multiple sclerosis	6.9e-05	0.0214	CbGeAlD
Vemurafenib—ABCG2—cerebellum—multiple sclerosis	5.8e-05	0.018	CbGeAlD
Vemurafenib—ABCC1—brain—multiple sclerosis	5.69e-05	0.0177	CbGeAlD
Vemurafenib—ABCG2—brain—multiple sclerosis	4.71e-05	0.0146	CbGeAlD
Vemurafenib—CYP3A4—nervous system—multiple sclerosis	4.3e-05	0.0133	CbGeAlD
Vemurafenib—CYP2D6—nervous system—multiple sclerosis	4.23e-05	0.0131	CbGeAlD
Vemurafenib—CYP3A4—central nervous system—multiple sclerosis	4.14e-05	0.0129	CbGeAlD
Vemurafenib—CYP2D6—central nervous system—multiple sclerosis	4.07e-05	0.0126	CbGeAlD
Vemurafenib—CYP2D6—cerebellum—multiple sclerosis	3.98e-05	0.0124	CbGeAlD
Vemurafenib—RAF1—Downstream signaling of activated FGFR—IL6—multiple sclerosis	3.37e-05	0.000294	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—GPR65—multiple sclerosis	3.33e-05	0.000291	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR2—multiple sclerosis	3.33e-05	0.00029	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB4—IL6—multiple sclerosis	3.32e-05	0.00029	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—SRM—multiple sclerosis	3.32e-05	0.00029	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—MAPK1—multiple sclerosis	3.27e-05	0.000286	CbGpPWpGaD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	3.26e-05	0.000285	CbGpPWpGaD
Vemurafenib—CYP2D6—brain—multiple sclerosis	3.23e-05	0.01	CbGeAlD
Vemurafenib—RAF1—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	3.2e-05	0.000279	CbGpPWpGaD
Vemurafenib—RAF1—Downstream signal transduction—IL6—multiple sclerosis	3.17e-05	0.000277	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR—IL6—multiple sclerosis	3.15e-05	0.000275	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-A—multiple sclerosis	3.15e-05	0.000275	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL3—multiple sclerosis	3.14e-05	0.000274	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by ERBB2—IL6—multiple sclerosis	3.14e-05	0.000274	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 signaling—IL6—multiple sclerosis	3.12e-05	0.000273	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD28—multiple sclerosis	3.09e-05	0.00027	CbGpPWpGaD
Vemurafenib—CYP2D6—Biological oxidations—POMC—multiple sclerosis	3.07e-05	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CNR1—multiple sclerosis	3.07e-05	0.000268	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	3.07e-05	0.000268	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL13—multiple sclerosis	3.05e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR1—multiple sclerosis	3.05e-05	0.000266	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CCR2—multiple sclerosis	3.04e-05	0.000265	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—PTPRC—multiple sclerosis	3.04e-05	0.000265	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PTGER4—multiple sclerosis	3.02e-05	0.000264	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TLR4—multiple sclerosis	3e-05	0.000261	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—PGR—multiple sclerosis	2.98e-05	0.00026	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD86—multiple sclerosis	2.95e-05	0.000257	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by FGFR in disease—IL6—multiple sclerosis	2.94e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Fc epsilon receptor (FCERI) signaling—IL6—multiple sclerosis	2.94e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—DAP12 interactions—IL6—multiple sclerosis	2.94e-05	0.000256	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DPB1—multiple sclerosis	2.94e-05	0.000256	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCR3—multiple sclerosis	2.92e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MMP9—multiple sclerosis	2.92e-05	0.000255	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—STAT3—multiple sclerosis	2.91e-05	0.000254	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR—IL6—multiple sclerosis	2.91e-05	0.000254	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—ITGA4—multiple sclerosis	2.9e-05	0.000253	CbGpPWpGaD
Vemurafenib—BRAF—Signaling by NGF—IL6—multiple sclerosis	2.89e-05	0.000252	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CD28—multiple sclerosis	2.89e-05	0.000252	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by EGFR in Cancer—IL6—multiple sclerosis	2.89e-05	0.000252	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IFNB1—multiple sclerosis	2.88e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—HLA-DRB1—multiple sclerosis	2.87e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by PDGF—IL6—multiple sclerosis	2.87e-05	0.000251	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—STAT3—multiple sclerosis	2.87e-05	0.00025	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD28—multiple sclerosis	2.86e-05	0.000249	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR2—multiple sclerosis	2.84e-05	0.000248	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD28—multiple sclerosis	2.83e-05	0.000247	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP27B1—multiple sclerosis	2.83e-05	0.000247	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—CYP24A1—multiple sclerosis	2.83e-05	0.000247	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ITGA4—multiple sclerosis	2.82e-05	0.000246	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40—multiple sclerosis	2.82e-05	0.000246	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—SRM—multiple sclerosis	2.81e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNB1—multiple sclerosis	2.8e-05	0.000245	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CTLA4—multiple sclerosis	2.78e-05	0.000243	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	2.77e-05	0.000241	CbGpPWpGaD
Vemurafenib—ALB—Selenium Micronutrient Network—IL6—multiple sclerosis	2.77e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD80—multiple sclerosis	2.77e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CXCL10—multiple sclerosis	2.76e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—ICAM1—multiple sclerosis	2.76e-05	0.000241	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—ALB—multiple sclerosis	2.66e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Neuronal System—MAPK1—multiple sclerosis	2.66e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD80—multiple sclerosis	2.66e-05	0.000232	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—MAPK1—multiple sclerosis	2.65e-05	0.000231	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TYK2—multiple sclerosis	2.64e-05	0.000231	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.63e-05	0.00023	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CNR1—multiple sclerosis	2.62e-05	0.000229	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CCR5—multiple sclerosis	2.61e-05	0.000228	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—MAPK1—multiple sclerosis	2.61e-05	0.000227	CbGpPWpGaD
Vemurafenib—CYP1A2—Biological oxidations—POMC—multiple sclerosis	2.6e-05	0.000227	CbGpPWpGaD
Vemurafenib—RAF1—NGF signalling via TRKA from the plasma membrane—IL6—multiple sclerosis	2.6e-05	0.000227	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—GPC5—multiple sclerosis	2.59e-05	0.000226	CbGpPWpGaD
Vemurafenib—BRAF—Disease—HLA-A—multiple sclerosis	2.55e-05	0.000222	CbGpPWpGaD
Vemurafenib—RAF1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—multiple sclerosis	2.52e-05	0.000219	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—VCAM1—multiple sclerosis	2.46e-05	0.000214	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQA1—multiple sclerosis	2.45e-05	0.000214	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	2.4e-05	0.00021	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL5—multiple sclerosis	2.38e-05	0.000208	CbGpPWpGaD
Vemurafenib—BRAF—Disease—APOE—multiple sclerosis	2.38e-05	0.000207	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CXCL10—multiple sclerosis	2.36e-05	0.000206	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—MAPK1—multiple sclerosis	2.36e-05	0.000206	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	2.34e-05	0.000204	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	2.34e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—TYK2—multiple sclerosis	2.33e-05	0.000204	CbGpPWpGaD
Vemurafenib—RAF1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.3e-05	0.000201	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DQB1—multiple sclerosis	2.29e-05	0.0002	CbGpPWpGaD
Vemurafenib—ABCC1—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.28e-05	0.000199	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—BCHE—multiple sclerosis	2.27e-05	0.000198	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—IL2—multiple sclerosis	2.25e-05	0.000197	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD86—multiple sclerosis	2.21e-05	0.000193	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL3—multiple sclerosis	2.17e-05	0.00019	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—SRM—multiple sclerosis	2.17e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD40LG—multiple sclerosis	2.17e-05	0.000189	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—IL2—multiple sclerosis	2.16e-05	0.000188	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD80—multiple sclerosis	2.15e-05	0.000188	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—RRM1—multiple sclerosis	2.15e-05	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCR5—multiple sclerosis	2.14e-05	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD8A—multiple sclerosis	2.14e-05	0.000187	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—GPC5—multiple sclerosis	2.14e-05	0.000187	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2RA—multiple sclerosis	2.11e-05	0.000184	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—CD4—multiple sclerosis	2.11e-05	0.000184	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PTGER4—multiple sclerosis	2.09e-05	0.000182	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MMP9—multiple sclerosis	2.08e-05	0.000182	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CD86—multiple sclerosis	2.06e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-B—multiple sclerosis	2.06e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—PGR—multiple sclerosis	2.06e-05	0.00018	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD86—multiple sclerosis	2.04e-05	0.000178	CbGpPWpGaD
Vemurafenib—RAF1—Cytokine Signaling in Immune system—IL6—multiple sclerosis	2.04e-05	0.000178	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL5—multiple sclerosis	2.03e-05	0.000177	CbGpPWpGaD
Vemurafenib—RAF1—Adaptive Immune System—CD4—multiple sclerosis	2.03e-05	0.000177	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD86—multiple sclerosis	2.02e-05	0.000176	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCR3—multiple sclerosis	2.02e-05	0.000176	CbGpPWpGaD
Vemurafenib—CYP3A4—Biological oxidations—POMC—multiple sclerosis	2.01e-05	0.000175	CbGpPWpGaD
Vemurafenib—ABCG2—Transmembrane transport of small molecules—ALB—multiple sclerosis	2.01e-05	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by NGF—IL6—multiple sclerosis	2e-05	0.000175	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD28—multiple sclerosis	2e-05	0.000175	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—BCHE—multiple sclerosis	2e-05	0.000174	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2RA—multiple sclerosis	1.98e-05	0.000173	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP24A1—multiple sclerosis	1.98e-05	0.000173	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—CYP27B1—multiple sclerosis	1.98e-05	0.000173	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR2—multiple sclerosis	1.96e-05	0.000171	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	1.94e-05	0.000169	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2RA—multiple sclerosis	1.93e-05	0.000168	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-A—multiple sclerosis	1.91e-05	0.000167	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—SPP1—multiple sclerosis	1.88e-05	0.000164	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—STAT3—multiple sclerosis	1.85e-05	0.000161	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCR5—multiple sclerosis	1.83e-05	0.00016	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TYK2—multiple sclerosis	1.81e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CNR1—multiple sclerosis	1.81e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Axon guidance—IL6—multiple sclerosis	1.81e-05	0.000158	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—GPC5—multiple sclerosis	1.81e-05	0.000158	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CCR5—multiple sclerosis	1.81e-05	0.000158	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2RA—multiple sclerosis	1.8e-05	0.000157	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CCR5—multiple sclerosis	1.79e-05	0.000156	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—RRM1—multiple sclerosis	1.77e-05	0.000155	CbGpPWpGaD
Vemurafenib—RAF1—Disease—HLA-A—multiple sclerosis	1.76e-05	0.000154	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—TGFB1—multiple sclerosis	1.76e-05	0.000153	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—HLA-A—multiple sclerosis	1.75e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TLR4—multiple sclerosis	1.75e-05	0.000152	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—HLA-DRB1—multiple sclerosis	1.74e-05	0.000152	CbGpPWpGaD
Vemurafenib—ALB—Platelet activation, signaling and aggregation—MAPK1—multiple sclerosis	1.72e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TGFB1—multiple sclerosis	1.72e-05	0.00015	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—TGFB1—multiple sclerosis	1.68e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—MAPK1—multiple sclerosis	1.68e-05	0.000147	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—POMC—multiple sclerosis	1.67e-05	0.000146	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—ICAM1—multiple sclerosis	1.67e-05	0.000146	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—APOE—multiple sclerosis	1.66e-05	0.000145	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.66e-05	0.000145	CbGpPWpGaD
Vemurafenib—RAF1—Hemostasis—MAPK1—multiple sclerosis	1.65e-05	0.000144	CbGpPWpGaD
Vemurafenib—RAF1—Disease—APOE—multiple sclerosis	1.64e-05	0.000144	CbGpPWpGaD
Vemurafenib—BRAF—Disease—CD4—multiple sclerosis	1.64e-05	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—CCL2—multiple sclerosis	1.64e-05	0.000143	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CXCL10—multiple sclerosis	1.63e-05	0.000142	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—APOE—multiple sclerosis	1.63e-05	0.000142	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD80—multiple sclerosis	1.61e-05	0.000141	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—TNF—multiple sclerosis	1.6e-05	0.00014	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	1.53e-05	0.000133	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	1.53e-05	0.000133	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CD80—multiple sclerosis	1.51e-05	0.000131	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—RRM1—multiple sclerosis	1.5e-05	0.000131	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—TYK2—multiple sclerosis	1.49e-05	0.00013	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD80—multiple sclerosis	1.49e-05	0.00013	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—MAPK1—multiple sclerosis	1.49e-05	0.00013	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD80—multiple sclerosis	1.47e-05	0.000129	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—POMC—multiple sclerosis	1.43e-05	0.000125	CbGpPWpGaD
Vemurafenib—ALB—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.43e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD86—multiple sclerosis	1.43e-05	0.000125	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL5—multiple sclerosis	1.41e-05	0.000123	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—CCL2—multiple sclerosis	1.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—GPC5—multiple sclerosis	1.4e-05	0.000122	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—APOE—multiple sclerosis	1.37e-05	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—TYK2—multiple sclerosis	1.36e-05	0.000119	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—SPP1—multiple sclerosis	1.3e-05	0.000114	CbGpPWpGaD
Vemurafenib—RAF1—Developmental Biology—IL6—multiple sclerosis	1.29e-05	0.000113	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IFNG—multiple sclerosis	1.27e-05	0.000111	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TYK2—multiple sclerosis	1.27e-05	0.000111	CbGpPWpGaD
Vemurafenib—BRAF—Disease—STAT3—multiple sclerosis	1.27e-05	0.000111	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCR5—multiple sclerosis	1.27e-05	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TYK2—multiple sclerosis	1.26e-05	0.00011	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2RA—multiple sclerosis	1.25e-05	0.000109	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TYK2—multiple sclerosis	1.24e-05	0.000109	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL2—multiple sclerosis	1.24e-05	0.000108	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—BCHE—multiple sclerosis	1.23e-05	0.000108	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—CD4—multiple sclerosis	1.23e-05	0.000107	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—APOE—multiple sclerosis	1.2e-05	0.000105	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MYC—multiple sclerosis	1.18e-05	0.000103	CbGpPWpGaD
Vemurafenib—BRAF—Disease—TGFB1—multiple sclerosis	1.18e-05	0.000103	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—POMC—multiple sclerosis	1.17e-05	0.000102	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.16e-05	0.000102	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—IL2—multiple sclerosis	1.16e-05	0.000101	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—RRM1—multiple sclerosis	1.16e-05	0.000101	CbGpPWpGaD
Vemurafenib—BRAF—Disease—MAPK1—multiple sclerosis	1.15e-05	0.000101	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—APOE—multiple sclerosis	1.15e-05	0.0001	CbGpPWpGaD
Vemurafenib—RAF1—Innate Immune System—IL6—multiple sclerosis	1.14e-05	9.96e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL1B—multiple sclerosis	1.14e-05	9.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—CD4—multiple sclerosis	1.14e-05	9.91e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL2—multiple sclerosis	1.13e-05	9.87e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—CD4—multiple sclerosis	1.13e-05	9.82e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Metabolism—ALB—multiple sclerosis	1.07e-05	9.33e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL2—multiple sclerosis	1.06e-05	9.23e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CD80—multiple sclerosis	1.04e-05	9.09e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—POMC—multiple sclerosis	1.03e-05	9.01e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.02e-05	8.88e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MMP9—multiple sclerosis	1e-05	8.73e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1e-05	8.73e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—POMC—multiple sclerosis	9.89e-06	8.63e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—CCL2—multiple sclerosis	9.68e-06	8.45e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—STAT3—multiple sclerosis	9.52e-06	8.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—MAPK1—multiple sclerosis	9.47e-06	8.26e-05	CbGpPWpGaD
Vemurafenib—ABCG2—Metabolism—ALB—multiple sclerosis	9.41e-06	8.21e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	9.12e-06	7.96e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—TGFB1—multiple sclerosis	9.06e-06	7.9e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—STAT3—multiple sclerosis	8.9e-06	7.76e-05	CbGpPWpGaD
Vemurafenib—ALB—Hemostasis—MAPK1—multiple sclerosis	8.88e-06	7.75e-05	CbGpPWpGaD
Vemurafenib—BRAF—Disease—IL6—multiple sclerosis	8.87e-06	7.74e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TYK2—multiple sclerosis	8.79e-06	7.67e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—STAT3—multiple sclerosis	8.79e-06	7.67e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—STAT3—multiple sclerosis	8.71e-06	7.6e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—MAPK1—multiple sclerosis	8.65e-06	7.55e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—BCHE—multiple sclerosis	8.62e-06	7.52e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MYC—multiple sclerosis	8.27e-06	7.21e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—TGFB1—multiple sclerosis	8.25e-06	7.2e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MYC—multiple sclerosis	8.17e-06	7.13e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—TGFB1—multiple sclerosis	8.15e-06	7.11e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MYC—multiple sclerosis	8.1e-06	7.06e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—MAPK1—multiple sclerosis	8.09e-06	7.06e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—TGFB1—multiple sclerosis	8.08e-06	7.05e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—MAPK1—multiple sclerosis	7.99e-06	6.97e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—MAPK1—multiple sclerosis	7.92e-06	6.91e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—APOE—multiple sclerosis	7.41e-06	6.47e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL2—multiple sclerosis	7.31e-06	6.38e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling by GPCR—IL6—multiple sclerosis	7.28e-06	6.35e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MMP9—multiple sclerosis	6.92e-06	6.04e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—BCHE—multiple sclerosis	6.65e-06	5.8e-05	CbGpPWpGaD
Vemurafenib—RAF1—Immune System—IL6—multiple sclerosis	6.65e-06	5.8e-05	CbGpPWpGaD
Vemurafenib—ALB—Metabolism—POMC—multiple sclerosis	6.37e-06	5.56e-05	CbGpPWpGaD
Vemurafenib—BRAF—Signaling Pathways—IL6—multiple sclerosis	6.21e-06	5.42e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—STAT3—multiple sclerosis	6.16e-06	5.37e-05	CbGpPWpGaD
Vemurafenib—RAF1—Disease—IL6—multiple sclerosis	6.14e-06	5.36e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—APOE—multiple sclerosis	6.12e-06	5.34e-05	CbGpPWpGaD
Vemurafenib—ABCC1—Disease—IL6—multiple sclerosis	6.09e-06	5.31e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MYC—multiple sclerosis	5.72e-06	4.99e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—TGFB1—multiple sclerosis	5.71e-06	4.98e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—MAPK1—multiple sclerosis	5.6e-06	4.88e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—POMC—multiple sclerosis	5.26e-06	4.59e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—APOE—multiple sclerosis	5.19e-06	4.52e-05	CbGpPWpGaD
Vemurafenib—CYP2D6—Metabolism—ALB—multiple sclerosis	4.79e-06	4.18e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—POMC—multiple sclerosis	4.45e-06	3.89e-05	CbGpPWpGaD
Vemurafenib—RAF1—Signaling Pathways—IL6—multiple sclerosis	4.3e-06	3.75e-05	CbGpPWpGaD
Vemurafenib—CYP1A2—Metabolism—ALB—multiple sclerosis	4.06e-06	3.54e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—APOE—multiple sclerosis	4e-06	3.49e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—POMC—multiple sclerosis	3.44e-06	3e-05	CbGpPWpGaD
Vemurafenib—CYP3A4—Metabolism—ALB—multiple sclerosis	3.13e-06	2.73e-05	CbGpPWpGaD
